AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6809322 — intervention group
Group type: COMPARATOR
Intervention: TPN and Standard nutrition (comparison)
Number of subjects: 36
Study 6809322 — intervention group
Group type: COMPARATOR
Intervention: TPN and Standard nutrition (subgroup analysis)
Number of subjects: 36
Study 6809322 — intervention group
Group type: COMPARATOR
Intervention: TPN and Standard nutrition (cycle-by-cycle analysis)
Number of subjects: 36
Study 6809322 — intervention group
Group type: COMPARATOR
Intervention: TPN and Standard nutrition (laboratory measures)
Number of subjects: 36
Study 30819084 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with clozapine
Number of subjects: 14
Study 30819084 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering agents
Number of subjects: 14
Study 28451013 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise 2X/week
Number of subjects: 100
Study 28451013 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise 3X/week
Number of subjects: 100
Study 26620120 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time sigmoidoscopy screening
Number of subjects: 98792
Study 26620120 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 98792
Study 23248197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg q.d. for moderate renal insufficiency and 25 mg q.d. for severe renal insufficiency)
Number of subjects: 426
Study 23248197 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (2.5 mg q.d., adjusted based on glycemic control to a 10 mg twice a day maximum dose)
Number of subjects: 426
Study 23248197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 426
Study 23248197 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 426
Study 23248197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 426
Study 21641106 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision protocol for type of delivery of breech presentations
Number of subjects: 1133
Study 18295467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc picolinate supplementation (22 mg daily for 8 weeks)
Number of subjects: 30
Study 18295467 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy non-smokers)
Number of subjects: 30
Study 17201084 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump
Number of subjects: 14
Study 17201084 — intervention group
Group type: COMPARATOR
Intervention: Centrifugal pump
Number of subjects: 14
Study 12490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological intervention (venlafaxine and paroxetine)
Number of subjects: 150
Study 12490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 150
Study 12490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 150
Study 12490772 — intervention group
Group type: COMPARATOR
Intervention: Improvement in symptoms
Number of subjects: 150
Study 12490772 — intervention group
Group type: COMPARATOR
Intervention: Baseline self-directedness score
Number of subjects: 150
Study 10917578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo 3 Fort
Number of subjects: 80
Study 10917578 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl rutoside (rutoside)
Number of subjects: 80
Study 8807761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antibiotic therapy plus early ultrasound-guided vaginal drainage
Number of subjects: 40
Study 8807761 — intervention group
Group type: COMPARATOR
Intervention: Intensive antibiotic therapy alone
Number of subjects: 40
Study 1461786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (40 mg/Kg/dose for 4 days)
Number of subjects: 32
Study 1461786 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amoxicillin (40 mg/Kg/dose for 4 days)
Number of subjects: 32
Study 6394131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 gm)
Number of subjects: 162
Study 6394131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 162
Study 6394131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 31464588 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychosocial program including cognitive stimulation, expansion of social support networks, and cognitive behaviour strategies.
Number of subjects: 0
Study 31464588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 30497484 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 25g
Number of subjects: 11
Study 30497484 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CAS) 25g
Number of subjects: 11
Study 30497484 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (MAL) 25g
Number of subjects: 11
Study 30497484 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric control (CON)
Number of subjects: 11
Study 27894522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-free braces
Number of subjects: 42
Study 27894522 — intervention group
Group type: COMPARATOR
Intervention: Conventional braces
Number of subjects: 42
Study 26111700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus standardised medical care (SMC)
Number of subjects: 298
Study 26111700 — intervention group
Group type: COMPARATOR
Intervention: Standardised medical care (SMC) alone
Number of subjects: 298
Study 23797954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ascorbic acid (AA) 4 g/d
Number of subjects: 110
Study 23797954 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 110
Study 21793327 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training for 1 year
Number of subjects: 23
Study 18821990 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontically moved teeth (29 premolars)
Number of subjects: 16
Study 18821990 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (19 premolars)
Number of subjects: 16
Study 18821990 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teeth (29 premolars)
Number of subjects: 16
Study 18821990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx method
Number of subjects: 16
Study 16611512 — intervention group
Group type: COMPARATOR
Intervention: Full-training group (n = 87 patients)
Number of subjects: 87
Study 16611512 — intervention group
Group type: COMPARATOR
Intervention: Focus group only group (n = 30 cases)
Number of subjects: 87
Study 14581270 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole as first-line therapy
Number of subjects: 0
Study 14581270 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen as first-line therapy
Number of subjects: 0
Study 10973651 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral placebo
Number of subjects: 41
Study 10973651 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6 mg every 4 weeks) plus oral continuous combined estradiol-norethisterone acetate add-back therapy daily for 24 weeks
Number of subjects: 41
Study 10973651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9356108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine in dextrose 7.5% in water
Number of subjects: 51
Study 9356108 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine in dextrose 7.5% in water
Number of subjects: 51
Study 8260566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 0
Study 8260566 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of remoxipride
Number of subjects: 0
Study 8260566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4087695 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dialysis
Number of subjects: 30
Study 4087695 — intervention group
Group type: COMPARATOR
Intervention: Isolated ultrafiltration
Number of subjects: 30
Study 4087695 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dialysis and isolated ultrafiltration
Number of subjects: 30
Study 31321951 — intervention group
Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation (2 mA) over Broca's area
Number of subjects: 16
Study 31321951 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 16
Study 31321951 — intervention group
Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation (2 mA)
Number of subjects: 16
Study 29889750 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 80
Study 29889750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27634316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice training
Number of subjects: 12
Study 27634316 — intervention group
Group type: COMPARATOR
Intervention: Self-directed textbook study (Control)
Number of subjects: 12
Study 24549267 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 80
Study 24549267 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 23237456 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1000
Study 23237456 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care as Usual (ECAU)
Number of subjects: 1000
Study 20380750 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel tablets
Number of subjects: 80
Study 20380750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (PDR(ICG))
Number of subjects: 96
Study 18795697 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT)
Number of subjects: 96
Study 18795697 — intervention group
Group type: COMPARATOR
Intervention: Bilirubin
Number of subjects: 96
Study 18795697 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR(ICG)
Number of subjects: 96
Study 16131466 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous block
Number of subjects: 50
Study 16131466 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacarpal block
Number of subjects: 50
Study 16131466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthecal block
Number of subjects: 50
Study 12704016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single counseling session targeting problem areas (condom use, negotiation, disclosure)
Number of subjects: 387
Study 12704016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session comprehensive intervention covering all 3 intervention domains
Number of subjects: 387
Study 12704016 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention plus 2 monthly booster sessions
Number of subjects: 387
Study 12704016 — intervention group
Group type: COMPARATOR
Intervention: 3-session diet and exercise attention-control condition
Number of subjects: 387
Study 10370741 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dipeptidase activity in urine (U/mol creatinine)
Number of subjects: 43
Study 10370741 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of dipeptidase (U/mmol creatinine)
Number of subjects: 43
Study 7526483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease (IHD) patients
Number of subjects: 83
Study 7526483 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease (PVD) patients
Number of subjects: 83
Study 7526483 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 83
Study 7526483 — intervention group
Group type: COMPARATOR
Intervention: All patients and controls
Number of subjects: 83
Study 2690621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg orally every 12 hours
Number of subjects: 100
Study 2690621 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime, 2.0 g intravenously every eight hours
Number of subjects: 100
Study 2690621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 100
Study 2690621 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 100
Study 2690621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 1101933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cyclical combination chemotherapy (CVP)
Number of subjects: 65
Study 1101933 — intervention group
Group type: COMPARATOR
Intervention: Total body radiation therapy
Number of subjects: 65
Study 1101933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodular lymphoma
Number of subjects: 65
Study 1101933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse lymphoma
Number of subjects: 65
Study 1101933 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 65
Study 30267930 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bathing with 4% chlorhexidine gluconate followed by water rinsing (CHGwr)
Number of subjects: 449
Study 30267930 — intervention group
Group type: COMPARATOR
Intervention: Daily bathing with standard soap (Control)
Number of subjects: 449
Study 28573374 — intervention group
Group type: EXPERIMENTAL
Intervention: TRPV1 and TRPA1 activators
Number of subjects: 22
Study 28573374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25912697 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg·kg(‐1)·day(‐1)
Number of subjects: 46
Study 25912697 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 10 µg·kg(‐1)·day(‐1)
Number of subjects: 46
Study 25912697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24369097 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTA)
Number of subjects: 250
Study 24369097 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 250
Study 20710133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise supported by The Coach Approach (CA)
Number of subjects: 53
Study 20710133 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal demonstration and follow up of exercise methods (EX)
Number of subjects: 53
Study 20710133 — intervention group
Group type: COMPARATOR
Intervention: Exercise suggested through written information only (INFO)
Number of subjects: 53
Study 17206496 — intervention group
Group type: EXPERIMENTAL
Intervention: dynamic vacuum orthosis with permitted mobilisation to 10 degrees ‐0 degrees ‐10 degrees at the ankle joint
Number of subjects: 27
Study 17206496 — intervention group
Group type: EXPERIMENTAL
Intervention: dynamic vacuum orthosis
Number of subjects: 27
Study 17206496 — intervention group
Group type: COMPARATOR
Intervention: synthetic cast
Number of subjects: 27
Study 16336518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) for 16 weeks
Number of subjects: 17
Study 16336518 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 17
Study 14686563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 0
Study 14686563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 14686563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10979055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control to levels lower than 130/85 mm Hg
Number of subjects: 0
Study 10979055 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Number of subjects: 0
Study 10979055 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 10979055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 10979055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Number of subjects: 0
Study 9364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn 24 hours/day
Number of subjects: 70
Study 9364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn only during the day
Number of subjects: 70
Study 9364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint worn only at night
Number of subjects: 70
Study 1397666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride/HCTZ (30 mg nicardipine three times daily)
Number of subjects: 43
Study 1397666 — intervention group
Group type: COMPARATOR
Intervention: Pindolol/HCTZ (5 mg pindolol three times daily)
Number of subjects: 43
Study 1397666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride/HCTZ
Number of subjects: 43
Study 1397666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Nicardipine/HCTZ and Pindolol/HCTZ)
Number of subjects: 43
Study 3925630 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of vinblastine, thiotepa, and 5-fluorouracil once a week
Number of subjects: 58
Study 3925630 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of vinblastine on days 1 and 2, thiotepa on day 3, and 5-fluorouracil on day 5, weekly
Number of subjects: 58
Study 31618208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive anthelminthic treatment
Number of subjects: 2881
Study 31618208 — intervention group
Group type: COMPARATOR
Intervention: HIV infected individuals on cART
Number of subjects: 2881
Study 30221885 — intervention group
Group type: EXPERIMENTAL
Intervention: EPNs from Semarang isolate
Number of subjects: 0
Study 30221885 — intervention group
Group type: COMPARATOR
Intervention: EPNs from commercial biopesticide
Number of subjects: 0
Study 30221885 — intervention group
Group type: EXPERIMENTAL
Intervention: EPNs from Semarang isolate and commercial biopesticide
Number of subjects: 0
Study 26321288 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV+RBV
Number of subjects: 459
Study 26321288 — intervention group
Group type: COMPARATOR
Intervention: TPV+PegIFN/RBV
Number of subjects: 459
Study 26321288 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV
Number of subjects: 459
Study 26321288 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r+DSV±RBV
Number of subjects: 459
Study 23844826 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective creams (PCs) applied at a low dose (2 mg/cm²)
Number of subjects: 20
Study 23844826 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective creams (PCs) applied at a high dose (20 mg/cm²)
Number of subjects: 20
Study 23844826 — intervention group
Group type: COMPARATOR
Intervention: Unprotected test sites
Number of subjects: 20
Study 22992160 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 45
Study 22992160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20479532 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive strength and endurance exercise program (12 weeks, 36 sessions, starting 4 to 6 weeks post-surgery)
Number of subjects: 48
Study 20479532 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive strength and endurance exercise program
Number of subjects: 48
Study 18047870 — intervention group
Group type: EXPERIMENTAL
Intervention: Social communication skills training (12 weekly group sessions, 1.5 hours each)
Number of subjects: 52
Study 18047870 — intervention group
Group type: EXPERIMENTAL
Intervention: Social communication skills training
Number of subjects: 52
Study 15919393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 microg)
Number of subjects: 100
Study 15919393 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley catheter
Number of subjects: 100
Study 12177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(‐1) x wk(‐1)
Number of subjects: 0
Study 12177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 3.0 to 9.0 m.c.g x kg(‐1) every 2 weeks
Number of subjects: 0
Study 12177793 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa at an initial dose of 150 U x kg(‐1) three times weekly
Number of subjects: 0
Study 12177793 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa at an initial dose of 40,000 U x wk(‐1)
Number of subjects: 0
Study 10023731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition, cognitive-behavioral obesity treatment plus exercise
Number of subjects: 39
Study 10023731 — intervention group
Group type: COMPARATOR
Intervention: Navy's usual treatment (exercise alone)
Number of subjects: 39
Study 7589031 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 200 mg
Number of subjects: 37
Study 7589031 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg
Number of subjects: 37
Study 7589031 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg
Number of subjects: 37
Study 7589031 — intervention group
Group type: EXPERIMENTAL
Intervention: Population typical values for a 70-kg person
Number of subjects: 37
Study 2025841 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized external radiation therapy to the pelvis or to the pelvis and para-aortic lymph nodes followed by one or two brachytherapy applications
Number of subjects: 626
Study 6404636 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g
Number of subjects: 6
Study 6404636 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 31931977 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 40
Study 31931977 — intervention group
Group type: COMPARATOR
Intervention: 1-year diabetes and weight management (DWM)
Number of subjects: 40
Study 29738286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-limiting excavation protocol using chemomechanical Carisolv gel/operating microscope
Number of subjects: 86
Study 29738286 — intervention group
Group type: COMPARATOR
Intervention: Selective removal to leathery dentin using rotary burs (control)
Number of subjects: 86
Study 26822592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-chi
Number of subjects: 153
Study 26822592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 153
Study 26822592 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 153